2 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Urinary Calculi: new trials by email Literature Review of Urinary Calculi trials Research Report on Urinary Calculi
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects NOV-001, NB1000S, NB2000P - Healthy Volunteers, Enteric Hyperoxaluria | Phase 1 / Phase 2 | Terminated | Novome Biotechnologies Inc | 153 | 2021-06-02 | 2023-05-17 |
| A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1) DCR-PH1, Placebo - Primary Hyperoxaluria Type 1 | Phase 1 | Terminated | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 41 | 2016-05-13 | 2024-07-11 |
Hyperoxaluria (2) · Kidney Calculi (2) · Genetic Diseases, Inborn (1) · Metabolic Diseases (1) · Primary hyperoxaluria type 1 (1) · Urologic Diseases (1)
Calculi (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Nephrolithiasis (2) · Pathological Conditions, Anatomical (2) · Pathological Conditions, Signs and Symptoms (2) · Urogenital Diseases (2) · Urolithiasis (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Nutritional and Metabolic Diseases (1) · Urologic Diseases (1)
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1) · Novome Biotechnologies Inc (1)
Canada (1) · Germany (1) · Netherlands (1) · United States (1)